First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion

First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion

With the continuous innovation of genomics, proteomics and molecular biological detection technology, the treatment of non-small cell lung cancer (NSCLC) has changed from traditional chemotherapy to immunotherapy and targeted therapy. Among them, molecular tumor markers targeting tyrosine kinase pat...

Full description

Bibliographic Details
Main Authors: Zhengguo LI, Ting WEI, Duo ZENG, Li ZHAO, Jianting ZHANG, Laixiu CHEN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2024-03-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
furmonertinib mesylate
epidermal growth factor receptor
exon 20 insertion mutation
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.11

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.11

Similar Items